Teresa Nimmo, MD
Endocrinology, Diabetes & Metabolism · Little Rock, ARNPI 1225253248
Payments from drug & device makers
Across 806 payments — averaging $35.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$10K
- Tandem Diabetes Care, Inc.$6K
- Abbott$1K
- Dexcom, Inc.$1K
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- plus $8K from 46 others
What the payments were for
- Consulting fees$4,50016%
- Speaking & faculty fees$6,20022%
- Travel & lodging$1,5535%
- Food & beverage$16,40157%
- Education$1360%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t:slim X2 insulin pump$3,850
- t-slim insulin pump$1,950
- Minimed 670G System$1,511
- MINIMED 780G$1,094
- Eversense$400
- CRYSVITA$285
- Korlym$123
- CRENESSITY$121
- TEPEZZA$121
- FREESTYLE LIBRE 3$119
- InPen$116
- MINIMED 770G$109
- FARXIGA$109
- DEXCOM G7 GSS (161)$106
- TWIIST$103
How this compares
$28,789 in reported general payments places this provider in the 65th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
See all endocrinology, diabetes & metabolism providers in Arkansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 333 | $399,207 |
| OzempicSemaglutide | 317 | $390,500 |
| TrulicityDulaglutide | 166 | $199,017 |
| JardianceEmpagliflozin | 116 | $108,399 |
| FarxigaDapagliflozin Propanediol | 149 | $105,816 |
| Tresiba Flextouch U-200Insulin Degludec | 107 | $82,082 |
| Humalog Kwikpen U-200Insulin Lispro | 31 | $56,764 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 31 | $43,022 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 90 | $41,725 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 42 | $40,645 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 53 | $36,775 |
| Humulin R U-500Insulin Regular, Human | 15 | $29,446 |
| Novolog FlexpenInsulin Aspart | 90 | $25,025 |
| NovologInsulin Aspart | 84 | $22,996 |
| TradjentaLinagliptin | 34 | $22,980 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $1,335 | $617,376621 claims |
| Novo NordiskOzempic, Novolog, Fiasp, Xultophy 100-3.6, Levemir | $1,264 | $448,218447 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $78 | $150,330173 claims |
| AstraZenecaFarxiga | $544 | $105,816149 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $805 | $17,33920 claims |
| MerckJanumet Xr | $207 | $5,57411 claims |
| AbbVieSynthroid | $490 | $4,84682 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
Other endocrinology, diabetes & metabolism in Little Rock
- James ThrasherLittle Rock$4M
- Richard GriffithsLittle Rock$925K
- Madhu BudhrajaLittle Rock$461K
- Irina LendelLittle Rock$87K
- Donald BodennerLittle Rock$51K
- Richard RappLittle Rock$47K
- Shunzhong BaoLittle Rock$40K
- Joseph HenskeLittle Rock$23K
- Nidhi JainLittle Rock$9K
- Archana JarathiLittle Rock$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.